Despite adequate posttransplantation therapy with immunosuppressives, graft-versus-host disease (GvHD) still remains one of the most common complications of allogeneic hematopoietic stem cell transplantation. [1] [2] [3] Its clinical manifestation is associated with significant morbidity and mortality. Clinically, acute GvHD mainly involves the skin, the liver and the gastrointestinal tract. [1] [2] [3] Initial treatment of acute GvHD consists of systemic corticosteroids and adaption of immunosuppressants.
The gastrointestinal tract is a prominent target organ involved in both acute and chronic GvHD. In order to minimize adverse drug reactions caused by high-dose systemic corticosteroids, the administration of topical corticosteroids when gastrointestinal GvHD presents is an attractive alternative. For over a decade, non-absorbable corticosteroids (e.g. budesonide and beclomethasone dipropionate) have been successfully used in the treatment of gastrointestinal GvHD. [1] [2] [3] [4] The successful use of these agents has been demonstrated in both adults and children. 1, 2, 4 In addition, recently published consensus guidelines support the use of these agents. [5] [6] [7] Budesonide is a potent, non-halogenated corticosteroid with high topical anti-inflammatory activity and a low systemic bioavailability when absorbed through mucosal surfaces, providing effective local immunosuppression and thus heeling of the inflammatory lesions. 8, 9 Budesonide has an extensive first-pass metabolism that lowers systemic bioavailability and the frequency of corticosteroid adverse reactions. Two oral formulations are available in Europe: budesonide capsules Entocort Õ (AstraZeneca, Brussels, Belgium) and Budenofalk Õ (Dr. Falk Pharma Benelux, Breda, The Netherlands), while Entocort Õ is available in the US and Canada. 10, 11 Both enteric-coated formulations are gastric acid degradation resistant and deliver budesonide into the distal small intestine and proximal colon. Budesonide capsules (Entocort TM EC) contain granules coated with methacrylic acid polymer protecting from dissolution in the stomach and the coating dissolves at a pH >5.5. The granules are embedded in a methylcellulose matrix which aims to control the release of budesonide in a time-dependent manner (until the drug reaches the ileum and ascending colon). 10 Budenofalk Õ capsules contain coated microgranules of budesonide and are designed to dissolve at a pH >6.4. 11 However, these capsules are large and patients with dysphagia or small children might have problems to swallow these capsules.
Our research question was drawn from a patient's case who suffered from a gastrointestinal GvHD and was unable to swallow the capsules without having them opened. The manufacturer's label states not to crush, chew, break or open the capsules. 10 Swallowing the entire capsules is the preferred way of administration. This raises a major concern for the appropriate administration of budesonide to patients with gastrointestinal GvHD, especially to very young children.
When searching the scientific literature (PubMed) or search engines (Google, Bing), no guidelines were found for this specific issue. However, opening the capsule and sprinkling the content over applesauce has been described without change in release properties of budesonide. 3, 12 From the literature data, we recommend the following for the administration of budesonide to children with gastrointestinal GvHD.
If the child is able to eat or drink . Encourage the child to swallow the entire budesonide capsule with water or applesauce or yogurt. . If the child has swallowing difficulties: open the capsule and disperse the content in applesauce or yogurt. Administer immediately to the patient.
If the child is not able to eat or drink
. Place a nasogastric tube with-whenever possible-external diameter of 8 French/Charrie`re size (a smaller external diameter will cause occlusion of the budesonide suspension in the tube). . Suspend the entire budesonide capsule in a small amount of applesauce or yogurt and dilute with 5 ml of water.
. Draw the suspension slowly in a catheter tip syringe.
. Connect the catheter tip syringe to the nasogastric tube. . Administer the ''suspension'' (containing the granules dispersed in applesauce) slowly through the nasogastric tube. . After administration, flush the tube with 20 ml of water as the granules may stick to the side of the enteral feeding tube.
In very small children or in patients for whom the above recommendations are not feasible, one might consider the use of another topical application (e.g. oral beclomethasone dipropionate in oil). 13, 14 Again, crushing the granules is not preferred or recommended by the manufacturer due the inactivation of budesonide in acid gastric environment.
In our specific patient, gastrointestinal GvHD started to resolve within one week after starting the administration of oral budesonide through the nasogastric tube.
Conclusion
Budesonide is a valuable steroid used in treatment of acute gastrointestinal GvHD. However, its use is limited by pH dependency which faces the pharmacist to difficulties in the appropriate administration of the drug to a child. As long as no other products are available, budesonide can be administered as described above. For those very young children with a nasogastric tube with a small external diameter, other treatment options should be evaluated.
